GLPwatch
Byetta for Polycystic ovary syndrome
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCByetta (exenatide) is not FDA-approved for polycystic ovary syndrome, and any use for this condition is off-label/investigational. Listed research explores its effects on weight loss, metabolic parameters, insulin resistance, and other related outcomes in PCOS, but does not establish approval or efficacy.
AI summary of the sources below.
| Drug | Byetta (exenatide) |
|---|---|
| Condition | Polycystic ovary syndrome |
| Approval status | Investigational / off-label |
| Research papers | 17 |
Byetta is not FDA-approved for polycystic ovary syndrome; the research below reflects investigational or off-label study only.
Research on exenatide for polycystic ovary syndrome (17)
- Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
- Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
- Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
- Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
- Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
- Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
- Exenatide improves ovarian and endometrial injury and preserves ovarian reserve in streptozocin induced diabetic rats.
- Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients.
- Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
- Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model.
- Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
- Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone.
- Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats.
- The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
- Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.
- Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta-analysis.
- Letter to Liu et al.'s "Efficacy of Exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome".